Nanobody Platform NanoY Develops Broad-Spectrum Antibiotic-Resistant Bacteria Antibody: A New Weapon Against Superbugs
Swiss biotech company NanoY Therapeutics' nanobody drug NY-401 targets MRSA superbugs with a 78% cure rate in Phase II trials, significantly outperforming vancomycin's 52%. Nanobodies offer a novel mechanism bacteria cannot easily develop resistance against.
Swiss biotech company NanoY Therapeutics published Phase II clinical trial results for its nanobody drug NY-401 in June 2028. NY-401 targets MRSA — a "superbug" that kills over 100,000 people globally each year.
Nanobodies are ultra-small antibodies naturally produced by camelids like llamas, only one-tenth the size of conventional antibodies. NanoY used AI-assisted protein engineering to modify nanobodies to penetrate MRSA's protective biofilm and directly attack bacterial cell walls.
In a 320-patient Phase II trial, NY-401 achieved a 78% clinical cure rate versus 52% for vancomycin, the current last-line antibiotic. NanoY CEO Thomas Huber said: "Nanobodies' advantage is that bacteria have difficulty developing resistance, as their attack mechanism differs completely from traditional antibiotics."
NY-401 is expected to enter Phase III trials in 2029. The WHO has placed NY-401 on its "prioritized antimicrobial drugs" list.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.